Who makes anti-infective therapy sitafloxacin?

anti-infective therapy sitafloxacin is developed by Shanghai Pulmonary Hospital, Shanghai, China.

What development phase is anti-infective therapy sitafloxacin in?

anti-infective therapy sitafloxacin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

anti-infective therapy sitafloxacin

Shanghai Pulmonary Hospital, Shanghai, China · FDA-approved active Small molecule Quality 2/100

Sitafloxacin, an anti-infective therapy developed by Shanghai Pulmonary Hospital, is currently marketed but lacks detailed revenue figures and primary indication data. The drug's key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. Without specific trial results or identified competitors, the primary risk remains the uncertainty of its competitive landscape and market sustainability post-patent expiry.

At a glance

Generic name	anti-infective therapy sitafloxacin
Sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

anti-infective therapy sitafloxacin CI brief — competitive landscape report
anti-infective therapy sitafloxacin updates RSS · CI watch RSS
Shanghai Pulmonary Hospital, Shanghai, China portfolio CI